← All trials
NCT04932005
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 29, 2021
- Primary completion
- Dec 10, 2021
- Completion date
- Dec 20, 2021
- First posted
- Jun 18, 2021
- Last posted
- Nov 2, 2021
- Enrollment
- 68
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Dizal (Jiangsu) Pharmaceutical Co., Ltd.Lead sponsor
- Frontage Laboratories, Inc.Overall official - principal investigator
- Frontage Laboratories, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.